|
|
| |
Clinical Trials and Research |
|
 |
 |
|
AC4R members are involved in a range of investigator-intitated and industry sponsored clinical trials.
Prospective Research in Memory Clinics (PRIME): is an observational database of de-identified data from patients with newly presenting dementia or mild cognitive impairment based on a similar Canadian project. The aim is to recruit 4,000 patients over three years and to follow those patients each for three years in a prospective observational study of clinical care and outcomes. Led by Professors David Ames, Henry Brodaty, Associate Professor Michael Woodward and Dr Karyn Boundy, the study has been approved by a number of human research ethics committees in Australia and currently being submitted for publication.
AC4R CLINICAL TRIAL STATUS
| |
Clinical Trial |
No. of patients required |
No. of patients enrolled |
End of enrollment date |
| 1 |
Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with moderate Alzheimer’s Disease treated with donepezil
|
competitive
|
|
2010 |
| 2 |
Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer's Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study (Protocol CL2-38093-005)
|
competirive |
|
2010 |
| 3 |
A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil (DIM18)
|
competitive |
|
2010 |
| 4 |
A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzheimer’s Disease (Protocol WN22018)
|
competitve |
|
May 2010 |
| 5 |
A Phase 2 Multicenter, Randomized, Double Blind, Placebo‑Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of PF‑04360365 in Patients with Mild to Moderate Alzheimer’s Disease (Protocol A9951002)
|
recruitment completed |
|
|
| 6 |
Open-Label Extension Study of 23 mg Donepezil SR in Patients with Moderate to Severe Alzheimer's Disease (E2020-G000-328)
|
recruitment completed |
|
|
| 7 |
A 24-week, multi-center, open-label evaluation of compliance and tolerability of the once-daily 10 cm² Exelon® Patch formulation in patients with probable Alzheimer’s disease
|
completed |
|
|
| 8 |
Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer's disease
|
|
|
|
| 9 |
Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo, H6L-MC-LFAN (b)
|
|
|
|
| 10 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers
|
competitive |
|
|
| 11 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers
|
competitive |
|
|
| 12 |
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer’s Disease MEM-MD-71
Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease (E2020-G000-326)
|
completed |
|
|
|
